Get notified of page updates
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy
Clinicaltrials.gov identifier:NCT04674306
Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy
Clinicaltrials.gov identifier:NCT04674306
Glossary on
off
About the Study
NOTE: This study is no longer recruiting people.
Researchers are studying the affects of this breast cancer vaccine on the immune system in the following groups:
- Prevention arm:
- people with an in , , or , who have not been diagnosed with cancer, and who are planning to undergo a risk-reducing mastectomy.
- Treatment arms:
- people diagnosed with 2 or stage 3 who have completed treatment and are considered at high risk for recurrence.
- people diagnosed with stage 2 or stage 3 triple-negative breast cancer who have completed chemotherapy and radiation and are currently receiving Keytruda (pembrolizumab).
This Study is Open To:
NOTE: This study is no longer recruiting people.
This Study is NOT Open To:
NOTE: This study is no longer recruiting people.